Medication Development in Alcoholism: Apremilast Versus Placebo

Alcohol Use Disorder Clinical Trial

Official title:

Medication Development for Protracted Abstinence in Alcoholism: Apremilast Versus Placebo

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03175549
• Other study ID #: U01AA025476
• Status: Completed
• Phase: Phase 2
• Start date: November 1, 2017
• Est. completion date: April 1, 2020

Study information

• Verified date: August 2022
• Source: The Scripps Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary hypotheses under test are that alcohol dependent subjects treated with apremilast will report decreased craving for alcohol following alcohol exposure in the laboratory and report significantly less drinking under naturalistic conditions, than those treated with placebo.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 51
• Est. completion date: April 1, 2020
• Est. primary completion date: April 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Male or female volunteers, 18-65 years of age

• Meets DSM-5 criteria for current alcohol use disorder of moderate or greater severity (AUD-MS)

• In the month prior to screening, reports drinking = 21 standard drinks per week if male, = 14 if female, with at least one heavy drinking day (= 5 males, = 4 females) per week.

• Subjects will not be seeking treatment because the medication studies are not treatment trials, and to avoid exposing treatment-seekers to alcohol cues

• Subjects must be abstinent a minimum of 3 days (but not more than 7 days) prior to the human lab session

• Negative BAC and a CIWA score of < 9 at time of lab session to eliminate acute alcohol or withdrawal effects on dependent measures.

• In acceptable health in the judgment of the study physician, on the basis of interview, medical history, physical exam, EKG, routine urine and blood chemistry.

• Females with childbearing potential must have a negative pregnancy test on the screening, randomization, and lab session visits and agree to use effective birth control for the duration required by a given study.

• Able to provide informed consent and understand questionnaires and study procedure

• Willing to comply with the provisions of the protocol and take daily oral medication.

Exclusion Criteria:

• Active suicidal ideation, as systematically assessed with the Columbia Suicide Severity Rating Scale.

• Meets DSM-5 criteria for a major psychiatric disorder, including mood or anxiety disorders or substance use disorders other than alcohol or nicotine

• Has a urine drug screen (UDS) positive for substances of abuse other than alcohol.

• Significant medical disorders that will increase potential risk or interfere with study participation as determined by the study physician

• Known hypersensitivity to apremilast

• Treatment within the month prior to screening with (1) an investigational drug, (2) medications which may negatively interact with study medications, or (3) drugs that may influence study outcomes (e.g., disulfiram [Antabuse], naltrexone [ReVia], acamprosate [Campral], anticonvulsants, or antidepressants).

• Ongoing treatment with medications that may increase risk, including prescribed, over-the-counter, and herbal preparations, as determined by the study physician.

• Sexually active female subjects with childbearing potential who are pregnant, nursing, or refuse to use effective methods of birth control for the duration required by a specific protocol.

• No fixed domicile and/or no availability by home or mobile telephone

• History of hypersensitivity to the study drug or the ingredients.

• Failure to take double-blind medication as prescribed.

Related Conditions & MeSH terms

• Alcohol Use Disorder
• Alcoholism

Intervention

Drug:
• Apremilast
Fixed oral dose of 90 mg/d following the standard titration for a total dosing duration of 14 days.
• Placebo
Identical placebo pills taken orally for 14 days

Locations

Country	Name	City	State
United States	The Scripps Research Institute Pearson Center for Alcoholism and Addiction Research	La Jolla	California

Sponsors (2)

Lead Sponsor	Collaborator
The Scripps Research Institute	National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Craving to Drink	Total Visual Analog Scale (VAS) scores of craving severity in response to in vivo alcohol cues. Higher scores indicate greater craving severity with a minimum score of 0 and a maximum score of 80.	1 hour on the last day of dosing (Day 14)
Secondary	Drinking	Number of standard drinks per day using the Timeline Followback Interview (TLFB). Total number of alcoholic drinks consumed per day with a minimum value of 0 and an undetermined maximum value.; Treatment effects on drinking were accessed during the 11 days of ad libidum and did not include the final three days of mandatory abstinence prior to cue reactivity testing on day 14 of dosing.	11 days (Treatment effects on drinking were accessed during the 11 days of ad libidum and did not include the final three days of mandatory abstinence prior to cue reactivity testing on day 14 of dosing.)